Concurrent HER2 vaccination and inhibition of kinase activity: Safety and immunogenicity

Immunotherapy

Volumn 4, Issue 7, 2012, Pages 671-674

  Albrecht, Huguette ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

breast cancer; combination therapy; HER2 vaccine; lapatinib; trastuzumab

Indexed keywords

ADJUVANT; CANCER VACCINE; DHER2 AS15 VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT PROTEIN; SIPULEUCEL T; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NOTE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

EID: 84864600144     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.61     Document Type: Note

References (16)

1. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 11, 793-800 (2011).
2. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J. Natl Cancer Inst. 104(8), 599-613 (2012).
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001).
4. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99, 628-638 (2007).
5. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplifcation of the HER-2/neu oncogene. Science 235, 177-182 (1987).
6. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
7. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin. Ther. 31(Pt 2), 2332-2348 (2009).
8. Ladjemi MZ, Jacot W, Chardes T et al. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol. Immunother. 59, 1295-1312 (2010).
9. Hamilton E, Blackwell K, Hobeika AC et al. Phase I clinical trial of HER2-specifc immunotherapy with concomitant HER2 kinase inhibtion. J. Transl Med. 10, 28 (2012).
10. Limentani SA, Curigliano G, Campone M et al. dHER2 cancer immunotherapeutic: clinical response in breast cancer patients is associated with an induction of functional antibodies and the generation of specifc T cells. Presented at: 30th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 13-16 December 2007 (Abstract 106, S7).
11. Hartman ZC, Wei J, Osada T et al. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic effcacy without oncogenicity. Clin. Cancer Res. 16, 1466-1477 (2010).
12. Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neu-specifc vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27, 4685-4692 (2009).
13. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin. Cancer Biol. 22(4), 327-334 (2012).
14. Norell H, Poschke I, Charo J et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J. Transl Med. 8, 53 (2010).
15. Postow M, Callahan MK, Wolchok JD. Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J. 17, 372-378 (2011).
16. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).